Solutions in Orphan Diseases
The Curry Rockefeller Group understands the unique challenges that companies face in an effort to develop safe and effective treatments for orphan conditions.
It is important to bring to market new medical therapies for rare or "orphan" diseases, which, by definition (in the United States), affect less than 200,000 people.
The Curry Rockefeller Group has a great deal of experience helping our clients develop communications strategies for many of the 6800 orphan diseases. Whether you need traditional or nontraditional medical education and communications, content development, or digital solutions, let the professionals at CRG help you.